Research map: Cretostimogene grenadenorepvec: promise beyond response

Papers in this map

1. The immune‐related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: analysis of individual patient data from IMvigor210 and IMvigor211 trials · Daniele Robesti · 2023 · 9 citations · Cited by this paper
2. Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research · 2026 · Related
3. Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin–unresponsive Carcinoma in Situ of the Bladder · Amanda A. Myers · 2025 · 9 citations · Cited by this paper
4. A step forward for precision oncology in thyroid cancer · 2026 · Related
5. Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial · Mark D Tyson · 2026 · 6 citations · Cited by this paper
6. RCP calls for UK to recognise air pollution as a public health emergency · 2026 · Related
7. French MPs vote for sharp cuts in cadmium content in fertilisers · 2026 · Related
8. The intermediate-risk gap in AI-based breast cancer stratification · 2026 · Related
9. Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial · 2026 · Related
10. Gastric cancer with peritoneal metastases: hype or hope for HIPEC? · 2026 · Related
11. Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS) · 2026 · Related
12. Development and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre study · 2026 · Related

Source: OpenAlex (CC0)